Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: A systematic review

Canadian Journal of Hospital Pharmacy

Volumn 64, Issue 3, 2011, Pages 182-191

  Stabler, Sarah N ^a   Ensom, Mary H H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Aminoglycosides; Extended interval dosing; Febrile neutropenia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZLOCILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; FLUCLOXACILLIN; GENTAMICIN; ISEPAMICIN; NETILMICIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

ADD ON THERAPY; ANTIBIOTIC THERAPY; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; IMMUNOCOMPROMISED PATIENT; NEPHROTOXICITY; OTOTOXICITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84881264010     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: 10.4212/cjhp.v64i3.1020     Document Type: Review

References (22)

1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106(10):2258-2266. (Pubitemid 43673249)
2. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections. Version 2.2009. Fort Washington (PA): National Comprehensive Cancer Network; 2009.
3. Aiken SK, Wetzstein GA. Once-daily aminoglycoside in patients with neutropenic fever. Cancer Control 2002;9(5):426-431. (Pubitemid 35204464)
4. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991;27 Suppl C:41-47.
5. US Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore (MD): Williams & Williams; 1996.
6. Hatala R, Dinh T, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997;24(5):810-815.
7. Rozdzinski E, Kern WV, Reichle A, Moritz T, Schmeiser T, Gaus W, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical theapy for febrile neutropenic patients. J Antimicrob Chemother 1993;31(4):585-598. (Pubitemid 23150137)
8. Leoni F, Ciolli S, Pascarella A, Fanci R, Caporale R, Ferrini P. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy 1993;39(2):147-152. (Pubitemid 23087071)
9. Herbrecht R, Blaise D, Espinouse D, Leblond V, Sadoun A, Sauvage C, et al. Isepamicin once daily plus ceftriaxone versus amikacin plus cetriaxone in febrile neutropenic patients. J Chemother 1995;7 Suppl 2:103-110.
10. Gibson J, Johnson L, Snowdon L, Joshua D, Young G, MacLeod C, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol 1993;58(1-2):63-72. (Pubitemid 23291838)
11. Torfoss D, Hoiby EA, Tangen JM, Holte H, Bo K, Meyer P, et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. J Antimicrob Chemother 2007;59(4):711-717. (Pubitemid 47073406)
12. Bakri FE, Pallett A, Smith AG, Duncombe AS. Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy. J Antimicrob Chemother 2000;45(3):383-386. (Pubitemid 30139252)
13. Cudillo L, Masi M, Scimo MT, Tribalto M, Cantonetti M, Criscuolo D, et al. Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients. J Chemother 1989;1(6):413-416. (Pubitemid 20074294)
14. Meunier F, Van der Auwera P, Aoun M, Ibrahim S, Tulkens PM. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study. J Antimicrob Chemother 1991;27 Suppl C:129-139.
15. Suwangool P, Aswapokee N, Sathapatayavongs B, Leelasuphasri S, Siritanaratkul N, Chuncharunee S, et al. Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone. J Med Assoc Thai 1993;76(6):314-318. (Pubitemid 24295829)
16. Warkentin D, Ippoliti C, Bruton J, Van Besien K, Champlin R. Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplant 1999;24(1):57-61. (Pubitemid 29346606)
17. Tod M, Lortholary O, Seytre D, Semaoun R, Uzzan B, Guillevin L, et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother 1998;42(4):849-856. (Pubitemid 28216366)
18. MacGowan AP, Bedford KA, Blundell E, Brown NM, Habib F, Hows J, et al. The pharmacokinetics of once daily gentamicin in neutropenic adults with haematological malignancy. J Antimicrob Agents Chemother 1994;34(5):809-812.
19. Peterson AK, Duffall SB. Population analysis of once-daily dosing of gentamicin in patients with neutropenia. Aust N Z J Med 1998;28(3):311-315. (Pubitemid 28322355)
20. Demczar DJ, Nafziger AN, Bertino JS. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 1997;41(5):1115-1119. (Pubitemid 27194194)
21. McNamara DR, Nafziger AN, Menhinick AM, Bertino JS. A dose-ranging study of gentamicin pharmacokinetics: implications for extended-interval aminoglycoside therapy. J Clin Pharmacol 2001;41(4):374-377. (Pubitemid 32274980)
22. Nicolau DP, Wu AH, Finocchiaro S, Udeh E, Chow MSS, Quintiliani R, et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit 1996;18(3):263-266. (Pubitemid 26159577)